Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

Johnson & Johnson (NYSE:JNJ) and Legend Biotech (NASDAQ:LEGN) said a long-term study showed their cell therapy Carvykti ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Multiple myeloma patients with COVID-19 have high rates of hospitalization, ICU admission, and death, according to researchers.

Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...